A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence

Megan Ryan,Daniel E. Falk,Joanne B. Fertig,Beatrice Rendenbach-Mueller,David A. Katz,Katherine A. Tracy,Eric C. Strain,Kelly E. Dunn,Kyle M. Kampman,Elizabeth Mahoney,Domenic A. Ciraulo,Laurie Sickles-Colaneri,Nassima Ait-Daoud,Bankole A. Johnson,Janet Ransom,Charles Scott,George F. Koob,Raye Z. Litten

A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence

2017

Megan Ryan
Daniel E. Falk
Joanne B. Fertig
Beatrice Rendenbach-Mueller
David A. Katz
Katherine A. Tracy
Eric C. Strain
Kelly E. Dunn
Kyle M. Kampman
Elizabeth Mahoney
Domenic A. Ciraulo
Laurie Sickles-Colaneri
Nassima Ait-Daoud
Bankole A. Johnson
Janet Ransom
Charles Scott
George F. Koob
Raye Z. Litten

A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence

Keywords:

Anesthesia
Psychopharmacology
Receptor antagonist
Randomized controlled trial
Psychology
Anxiety
Schizophrenia
Placebo
Alcohol dependence
Internal medicine
Alcohol use disorder
Psychiatry
Side effect
Clinical trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations